Brain Trust Accelerator Fund is a venture capital firm founded in 2006 and based in Burlingame, California. See contact routes.
Brain Trust Accelerator Fund is a venture capital firm founded in 2006 and based in Burlingame, California, that specializes in translational-stage investments addressing the diagnosis and treatment of brain-related diseases. The firm’s investment thesis targets early-stage companies in the neuroscience sector, with a geographic focus primarily on the United States and a sector emphasis on therapeutics, medtech, clinical diagnostics, and technologies crossing the blood-brain barrier. Typical investment checks range from $5 million to $20 million, and the fund commonly participates in Seed, Series A, and Series B rounds. Notable portfolio companies include Chase Therapeutics, NeuroTherapia, and Satoris, reflecting its commitment to both therapeutic and medical technology solutions for neurological disorders. The fund distinguishes itself through a disease-focused orientation rather than a generalist healthcare mandate, aiming to translate promising science into clinical applications for patients with unmet neurological needs. While the firm has generated top-tier returns with Fund I and benefited up to ten million patients, there is no publicly do
Details on this firm come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Burlingame.
Investors like Brain Trust Accelerator Fund · Full investor directory · Investor access · Company funding database